SITE001-0066

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-05-18

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-11 (study day 78); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-01 (study day 160); relationship: N

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 176); relationship: N

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-01 (study day 280); relationship: Y

mild assessed

Grade 1 Alopecia — outcome: UNKNOWN; onset 2023-04-04 (study day 314); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-07-21 (study day 422); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-08-26 (study day 458); relationship: N

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-23 (study day 547); relationship: not assessed

severe assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-16 (study day 601); relationship: not assessed

Data queries

No data queries.